MARKET

TECH

TECH

Bio-Techne
NASDAQ

Real-time Quotes | Nasdaq Last Sale

408.23
-14.82
-3.50%
After Hours: 408.23 0 0.00% 17:33 05/10 EDT
OPEN
421.13
PREV CLOSE
423.05
HIGH
423.30
LOW
407.91
VOLUME
259.22K
TURNOVER
--
52 WEEK HIGH
444.83
52 WEEK LOW
228.67
MARKET CAP
15.84B
P/E (TTM)
93.04
1D
5D
1M
3M
1Y
5Y
BRIEF-Bio-Techne Says Multisite Study Demonstrates Utility Of Asuragen Kit
reuters.com · 13h ago
Bio-Techne Provides an Update on its AmplideX
In the study, the AmplideX® Kit was evaluated independently at GenePhile Bioscience Laboratory in Taiwan; the University Medical Center Groningen in the Netherlands; Turku University Hospital
Benzinga · 14h ago
Multisite Study Demonstrates Utility of Asuragen Kit for Identifying Variants Linked to Spinal Muscular Atrophy
, /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Asuragen, a Bio-Techne brand, and scientific collaborators have published the results of a multisite evaluation study of the AmplideX PCR/CE SMA Plus* Kit that validates its perfo...
PR Newswire - PRF · 14h ago
DJ Bio-Techne Corporation CEO Chuck Kummeth on Q3 2021 Results -- Earnings Call Transcript >TECH
Dow Jones · 1d ago
10-Q: BIO-TECHNE CORP
(EDGAR Online via COMTEX) -- ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following management...
Edgar Online - (EDG = 10Q, 10K) · 3d ago
Growth of the Glycomics / Glycobiology Market to be Propelled by Proliferating Cancer and Diabetic Diseases by a Notable CAGR During 2020 - 2028
May 07, 2021 (AmericaNewsHour) -- Research Nester published a report titled "Glycomics / GlycobiologyMarket: Global Demand Analysis & Opportunity Outlook...
AmericaNewsHour · 3d ago
--Baird Adjusts Price Target on Bio-Techne to $430 From $410, Keeps Outperform Rating
MT Newswires · 3d ago
Glycomics / Glycobiology Market Size, Analysis, and Forecast Report 2028
May 07, 2021 (AmericaNewsHour) -- Research Nester published a report titled "Glycomics / Glycobiology Market: Global Demand Analysis & Opportunity...
AmericaNewsHour · 3d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TECH. Analyze the recent business situations of Bio-Techne through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TECH stock price target is 453.89 with a high estimate of 500.00 and a low estimate of 410.00.
EPS
Institutional Holdings
Institutions: 578
Institutional Holdings: 39.29M
% Owned: 101.26%
Shares Outstanding: 38.80M
TypeInstitutionsShares
Increased
151
1.09M
New
63
1.07M
Decreased
145
2.18M
Sold Out
41
226.13K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.01%
Pharmaceuticals & Medical Research
-0.44%
Key Executives
Chairman/Independent Director
Robert Baumgartner
President/Chief Executive Officer/Director
Charles Kummeth
Chief Financial Officer/Executive Vice President - Finance
James Hippel
Corporate Executive
David Eansor
Corporate Executive
Kim Kelderman
Senior Vice President/General Counsel/Secretary
Brenda Furlow
Independent Director
Julie Bushman
Independent Director
John Higgins
Independent Director
Joseph Keegan
Independent Director
Roeland Nusse
Independent Director
Alpna Seth
Independent Director
Randolph Steer
Independent Director
Rupert Vessey
Declaration Date
Dividend Per Share
Ex-Div Date
05/06/2021
Dividend USD 0.32
05/14/2021
02/02/2021
Dividend USD 0.32
02/11/2021
11/05/2020
Dividend USD 0.32
11/13/2020
08/04/2020
Dividend USD 0.32
08/17/2020
04/30/2020
Dividend USD 0.32
05/08/2020
02/04/2020
Dividend USD 0.32
02/13/2020
10/29/2019
Dividend USD 0.32
11/07/2019
08/06/2019
Dividend USD 0.32
08/15/2019
04/30/2019
Dividend USD 0.32
05/09/2019
02/05/2019
Dividend USD 0.32
02/14/2019
--
Dividend USD 0.32
11/08/2018
--
Dividend USD 0.32
08/16/2018
--
Dividend USD 0.32
05/11/2018
--
Dividend USD 0.32
02/15/2018
--
Dividend USD 0.32
11/09/2017
--
Dividend USD 0.32
08/16/2017
--
Dividend USD 0.32
05/17/2017
--
Dividend USD 0.32
02/15/2017
10/31/2016
Dividend USD 0.32
11/09/2016
08/17/2016
Dividend USD 0.32
08/25/2016
04/26/2016
Dividend USD 0.32
05/11/2016
--
Dividend USD 0.32
02/10/2016
--
Dividend USD 0.32
11/10/2015
08/06/2015
Dividend USD 0.32
08/13/2015
05/05/2015
Dividend USD 0.32
05/13/2015
02/03/2015
Dividend USD 0.32
02/11/2015
10/30/2014
Dividend USD 0.32
11/06/2014
08/11/2014
Dividend USD 0.31
08/19/2014
04/28/2014
Dividend USD 0.31
05/07/2014
02/04/2013
Dividend USD 0.31
02/12/2014
10/31/2013
Dividend USD 0.31
11/07/2013
08/06/2013
Dividend USD 0.3
08/14/2013
04/30/2013
Dividend USD 0.3
05/08/2013
02/05/2013
Dividend USD 0.3
02/13/2013
10/26/2012
Dividend USD 0.3
11/01/2012
07/31/2012
Dividend USD 0.28
08/08/2012
05/01/2012
Dividend USD 0.28
05/09/2012
01/31/2012
Dividend USD 0.28
02/08/2012
10/27/2011
Dividend USD 0.28
11/03/2011
08/02/2011
Dividend USD 0.27
08/10/2011
05/03/2011
Dividend USD 0.27
05/11/2011
02/01/2011
Dividend USD 0.27
02/09/2011
10/28/2010
Dividend USD 0.27
11/04/2010
--
Dividend USD 0.26
08/12/2010
05/04/2010
Dividend USD 0.26
05/12/2010
02/02/2010
Dividend USD 0.26
02/10/2010
10/29/2009
Dividend USD 0.26
11/05/2009
08/04/2009
Dividend USD 0.25
08/13/2009
04/28/2009
Dividend USD 0.25
05/06/2009
02/03/2009
Dividend USD 0.25
02/11/2009
More
About TECH
Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through two segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences reporting segment supplies specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and reagents, to the biotechnology community. The Protein Sciences segment also provides an array of platforms useful in various areas of protein analysis. The Diagnostics and Genomics reporting segment provides blood chemistry and blood gas quality controls, hematology instrument controls, diagnostics immunoassays and other bulk and custom reagents for the in vitro diagnostic market.

Webull offers kinds of BIO-TECHNE Corp stock information, including NASDAQ:TECH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TECH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TECH stock methods without spending real money on the virtual paper trading platform.